Key result
Sugammadex for reversal of neuromuscular blockade was not associated with an increased risk of bleeding events within 24 hours compared to usual care (2.9% vs 4.1%; RR 0.70, 95% CI 0.38-1.29).
Why the study?
Does sugammadex increase bleeding events in surgical patients receiving thromboprophylaxis compared to usual care?
Population
1,198 randomized patients receiving thromboprophylaxis and undergoing hip or knee joint replacement or hip…
Comparison
Sugammadex 4 mg/kg for reversal of rocuronium… vs Usual care (neostigmine or spontaneous recovery).
Design
RCT, randomized, stratified by thromboprophylaxis and renal status, double-blind
Follow-up
24 h
Authors
Loading...
Supports sugammadex reversal in thromboprophylaxed surgical patients; confirms clinical bleeding safety in this RCT.
RCT (n=1,198)
Double-blind
randomized
Does sugammadex increase bleeding events in surgical patients receiving thromboprophylaxis compared to usual care?
Relative Risk: 0.7 (95% CI 0.38–1.29)
Absolute Event Rate: 2.9% vs 4.1%
Sugammadex causes transient increases in coagulation times but does not increase clinical bleeding risk compared to usual care in orthopedic surgery patients.
Rahe‐Meyer et al. (2014) conducted an RCT in Surgical patients undergoing hip or knee joint replacement or hip fracture surgery (n=1,198). Sugammadex vs. Usual care (neostigmine or spontaneous recovery) was evaluated on Bleeding events within 24 h (RR 0.70, 95% CI 0.38 to 1.29). Sugammadex for reversal of neuromuscular blockade was not associated with an increased risk of bleeding events within 24 hours compared to usual care (2.9% vs 4.1%; RR 0.70, 95% CI 0.38-1.29).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: